RxDoctor Payments Data

Michael Patton

Urology · Tucson, AZNPI 1669859153

Payments from drug & device makers

$2,493in general payments, 2019–2025

Across 92 payments — averaging $27.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$427
  • Sumitomo Pharma America, Inc.$201
  • Astellas Pharma US Inc$146
  • AbbVie$145
  • Agiliti Surgical, Inc.$139
  • Urogen Pharma, Inc.$133
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$2,35995%
  • Education$1345%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,493 in reported general payments places this provider in the 40th percentile of 269 urology providers in Arizona.

See all urology providers in Arizona

Medicare billing

Part B allowed, 2024
$227,470
Medicare patients
451
Services billed
3,493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron239$175,047
GemtesaVibegron41$39,553
OrgovyxRelugolix12$32,110
Mirabegron ErMirabegron11$6,463
Tamsulosin Hcl428$5,479
Potassium Citrate ErPotassium Citrate22$2,026
Finasteride177$1,902
Estradiol17$1,196
Oxybutynin Chloride ErOxybutynin Chloride48$838
Cephalexin58$529
Alfuzosin Hcl ErAlfuzosin Hcl11$312
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip15$280
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim78$216
Ciprofloxacin Hcl41$144
Oxybutynin Chloride20$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$146$175,047239 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$201$71,66253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 269 urology providers in Arizona.

Other urology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →